三爱健康集团二零二四年中期报告

Corporate Information BOARD OF DIRECTORSExecutive Directors Mr. Chen ChengqingProfessor Zhang RongqingMr. Gao Borui(resigned with effect from 28 June 2024)Mr. Yuan ChaoyangMr. She HaoMr. Xie Haijing(appointed with effect from 28 June 2024) Non-executive Director Mr. Xiu Yuan(resigned with effect from 28 June 2024) Independent Non-executive Directors Professor Zhu Yi ZhunMr. Khor Khie Liem AlexMr. Zhang Ruigen COMPANY SECRETARYMs. Li Yuen Shan AUTHORIZED REPRESENTATIVES Mr. She HaoMs. Li Yuen Shan AUDIT COMMITTEE Mr. Khor Khie Liem Alex(Chairman)Professor Zhu Yi ZhunMr. Zhang Ruigen REMUNERATION COMMITTEE Mr. Khor Khie Liem Alex(Chairman)Professor Zhu Yi ZhunMr. Zhang RuigenProfessor Zhang Rongqing Corporate Information NOMINATION COMMITTEE Mr. Zhang Ruigen(Chairman)Professor Zhu Yi ZhunMr. Khor Khie Liem AlexProfessor Zhang Rongqing AUDITOR Forvis Mazars CPA Limited(formerly known as Mazars CPA Limited) HONG KONG LEGAL ADVISOR 183401 Commerce & Finance Law Officesin Association with Eric Chow & Co3401, Alexandra House18 Chater RoadCentral, Hong Kong PRINCIPAL BANKERS Nanyang Commercial Bank LimitedHang Seng Bank LimitedChina Construction BankIndustrial and Commercial Bank of China LimitedChina CITIC Bank Corporation Limited REGISTERED OFFICE Grand PavilionHibiscus Way802 West Bay RoadP.O. Box 31119KY1-1205Cayman Islands Grand PavilionHibiscus Way802 West Bay RoadP.O. Box 31119KY1-1205Cayman Islands Corporate Information PRINCIPAL PLACE OF BUSINESS INHONG KONG 5775 Unit 5, 7/F.Nanyang Plaza57 Hung To RoadKwun TongKowloon, Hong Kong SHARE REGISTRARS AND TRANSFEROFFICES Royal Bank of Canada Trust Company(Cayman) Limited4th Floor, Royal Bank House24 Shedden Road, George TownGrand Cayman KY1-1110Cayman Islands Principal share registrar and transfer officeRoyal Bank of Canada Trust Company(Cayman) Limited4th Floor, Royal Bank House24 Shedden Road, George TownGrand Cayman KY1-1110Cayman Islands 18317M Hong Kong branch share registrar and transfer officeComputershare Hong Kong Investor Services Limited17M FloorHopewell Centre183 Queen’s Road EastWanchai, Hong Kong 1889 STOCK CODE1889 www.1889hk.com WEBSITEwww.1889hk.com Management Discussion and Analysis The board (the “Board”) of directors (the “Directors”)of Sanai Health Industry Group Company Limited(“Sanai Health Industry” or the “Company”) herebypresents the unaudited condensed consolidatedfinancial statements of the Company and itssubsidiaries (collectively referred to the “Group”) forthe six-month period ended 30 June 2024 (the “CurrentPeriod”), together with the comparative figures for thecorresponding period in 2023. BUSINESS REVIEW During the Current Period, the Group was principallyengaged in three businesses: (i) pharmaceuticalproduct business; (ii) finance leasing business; and (iii)genetic testing and molecular diagnostic services. Thethree businesses are stated as below: (i)(ii)(iii) Pharmaceutical Products Business Since August 2022, Fujian Rui Chuang Health IndustryCompany Limited* ()(“Fujian Rui Chuang”), the Company’s indirectwholly-owned subsidiary, has remained to be thecore production centre as well as the exclusive saleschannel of the Group’s own developed pharmaceuticalproducts during the Current Period. As highlightedin the Company’s 2023 Annual Report, the negativeimpact to our pharmaceutical products businessbrought by a very substantial increase in the generalcost as well as a shortage in the volume of supply oftraditional Chinese herbal materials in the PRC sincethe start of the year of 2023 has continued in the firsthalf year of 2024, which has still adversely affectedthe gross profit margin as well as the volume of salesof our own developed pharmaceutical products in theCurrent Period. Management Discussion and Analysis Fujian Zhixin Medicine Co., Limited* () (“Fujian Zhixin”), an indirect wholly-ownedsubsidiary of the Company, continued to act as a salesagent nationwide for the herbal medical materials,Chinese herbal medicine, Chinese patent medicine,chemical drug preparations, antibiotic preparations,biochemical pharmaceuticals, biological products,healthcare products and food products. 51%33.1533.15 Beijing Bafuluo Technology Co., Ltd.* () (“Beijing Bafuluo”), an indirect wholly-owned subsidiary of the Company, has entered into aSales & Purchase Agreement on 1 March 2024 with Mr.Xie Haijing (the “Vendor”) in relation to the acquisitionof 51% controlling shareholding of Beijing HangyangHealth Technology Co., Ltd.* () (”Beijing Hangyang”) for a cash considerationof RMB33.15 million (the “Acquisition”), please referto the Company’s announcements dated 1 March2024 and 18 March 2024 (the “Announcements”).The Acquisition has been completed on 14 May 2024whereas the consideration of RMB33.15 million hasbeen fully settled and that the registration of the EquityTransfer in the PRC has been legally completed. Management Discussion and Analysis As explained in the Announcements, the Board of